- €897.31m
- €513.16m
- €535.18m
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Biontech Closes Acquisition Of CureVac
Brief: BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025
Brief: Curevac Reaffirms Its Expected Cash Runway Into 2028
Brief: Biontech Commences Public Exchange Offer For All Outstanding Shares Of Curevac N.V.
Brief: German Federal Cartel Office Approves Acquisition Of Curevac By Biontech
GSK among top FTSE gainers after $370 mln mRNA patent settlement
CureVac settles patent dispute litigation with Pfizer and BioNTech (updated)
Curevac and GSK agree to resolve patent dispute litigation with Pfizer and BioNTech
Brief: Curevac Announces Resolution Of Patent Litigation With Pfizer/Biontech
DB expects EU pharma 'malaise' to continue amid US headwinds
Brief: CureVac agrees to pay Biontech termination fee Of $43.8 mln under specified circumstances
U.S. RESEARCH ROUNDUP- Darden Restaurants, EOG Resources, Oracle
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
German economy ministry says it supports BioNTech/CureVac transaction
CureVac jumps on BioNTech's $1.25 billion all-stock acquisition deal
BioNTech to acquire CureVac in $1.25 billion all-stock deal (updated)
BioNTech agrees to acquire former COVID vaccine rival CureVac